Terms: = Skin cancer AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184 AND Treatment
55 results:
1. Targeting the CXCL12/cxcr4 pathway to reduce radiation treatment side effects.
Chaudary N; Hill RP; Milosevic M
Radiother Oncol; 2024 May; 194():110194. PubMed ID: 38447871
[TBL] [Abstract] [Full Text] [Related]
2. Tozasertib activates anti-tumor immunity through decreasing regulatory T cells in melanoma.
Wang Q; Liu W; Zhou H; Lai W; Hu C; Dai Y; Li G; Zhang R; Zhao Y
Neoplasia; 2024 Feb; 48():100966. PubMed ID: 38237304
[TBL] [Abstract] [Full Text] [Related]
3. A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of whim syndrome.
McDermott DH; Velez D; Cho E; Cowen EW; DiGiovanna JJ; Pastrana DV; Buck CB; Calvo KR; Gardner PJ; Rosenzweig SD; Stratton P; Merideth MA; Kim HJ; Brewer C; Katz JD; Kuhns DB; Malech HL; Follmann D; Fay MP; Murphy PM
J Clin Invest; 2023 Oct; 133(19):. PubMed ID: 37561579
[TBL] [Abstract] [Full Text] [Related]
4. Differential Response of Mycosis Fungoides Cells to Vorinostat.
Bordeaux ZA; Reddy SV; Lee K; Lu W; Choi J; Miller M; Roberts C; Pollizzi A; Kwatra SG; Kwatra MM
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175780
[TBL] [Abstract] [Full Text] [Related]
5. Mavorixafor, an Orally Bioavailable cxcr4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma.
Andtbacka RHI; Wang Y; Pierce RH; Campbell JS; Yushak M; Milhem M; Ross M; Niland K; Arbeit RD; Parasuraman S; Bickley K; Yeung CC; Aicher LD; Smythe KS; Gan L
Cancer Res Commun; 2022 Aug; 2(8):904-913. PubMed ID: 36923305
[TBL] [Abstract] [Full Text] [Related]
6. The involvement of a chemokine receptor antagonist CTCE-9908 and kynurenine metabolites in cancer development.
Nkandeu DS; Basson C; Joubert AM; Serem JC; Bipath P; Nyakudya T; Hlophe Y
Cell Biochem Funct; 2022 Aug; 40(6):608-622. PubMed ID: 35789495
[TBL] [Abstract] [Full Text] [Related]
7. Preclinical platforms to study therapeutic efficacy of human γδ T cells.
Ou L; Wang H; Huang H; Zhou Z; Lin Q; Guo Y; Mitchell T; Huang AC; Karakousis G; Schuchter L; Amaravadi R; Guo W; Salvino J; Herlyn M; Xu X
Clin Transl Med; 2022 Jun; 12(6):e814. PubMed ID: 35731974
[TBL] [Abstract] [Full Text] [Related]
8. Current Challenges in Targeting Tumor Desmoplasia to Improve the Efficacy of Immunotherapy.
Kasperska A; Borowczak J; Szczerbowski K; Stec E; Ahmadi N; Szylber Ł
Curr Cancer Drug Targets; 2021; 21(11):919-931. PubMed ID: 34525931
[TBL] [Abstract] [Full Text] [Related]
9. Pro-pigmentary action of 5-fluorouracil through the stimulated secretion of CXCL12 by dermal fibroblasts.
Liao ZK; Hu SH; Han BY; Qiu X; Jiang S; Lei TC
Chin Med J (Engl); 2021 Sep; 134(20):2475-2482. PubMed ID: 34507320
[TBL] [Abstract] [Full Text] [Related]
10. Phase 1 study of ibrutinib and the cxcr4 antagonist ulocuplumab in cxcr4-mutated Waldenström macroglobulinemia.
Treon SP; Meid K; Hunter ZR; Flynn CA; Sarosiek SR; Leventoff CR; White TP; Cao Y; Roccaro AM; Sacco A; Demos MG; Guerrera ML; Kofides A; Liu X; Xu L; Patterson CJ; Munshi M; Tsakmaklis N; Yang G; Ghobrial IM; Branagan AR; Castillo JJ
Blood; 2021 Oct; 138(17):1535-1539. PubMed ID: 34289017
[TBL] [Abstract] [Full Text] [Related]
11. Melanoma-derived extracellular vesicles skew neutrophils into a pro-tumor phenotype.
Guimarães-Bastos D; Frony AC; Barja-Fidalgo C; Moraes JA
J Leukoc Biol; 2022 Mar; 111(3):585-596. PubMed ID: 34043843
[TBL] [Abstract] [Full Text] [Related]
12. A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and ImmunOtherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma.
Lin C; Ballah T; Nottage M; Hay K; Chua B; Kenny L; Thomas P; Teng M; Keller J; Le T; Edmunds J; Hughes B
Radiat Oncol; 2021 Apr; 16(1):69. PubMed ID: 33836800
[TBL] [Abstract] [Full Text] [Related]
13. Harnessing the polyamine transport system to treat BRAF inhibitor-resistant melanoma.
Alexander ET; El Naggar O; Fahey E; Mariner K; Donnelly J; Wolfgang K; Phanstiel O; Gilmour SK
Cancer Biol Ther; 2021 Mar; 22(3):225-237. PubMed ID: 33602034
[TBL] [Abstract] [Full Text] [Related]
14. Circular RNA circ_0020710 drives tumor progression and immune evasion by regulating the miR-370-3p/CXCL12 axis in melanoma.
Wei CY; Zhu MX; Lu NH; Liu JQ; Yang YW; Zhang Y; Shi YD; Feng ZH; Li JX; Qi FZ; Gu JY
Mol Cancer; 2020 May; 19(1):84. PubMed ID: 32381016
[TBL] [Abstract] [Full Text] [Related]
15. Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma.
Andrews JM; Schmidt JA; Carson KR; Musiek AC; Mehta-Shah N; Payton JE
EBioMedicine; 2019 Aug; 46():170-183. PubMed ID: 31358475
[TBL] [Abstract] [Full Text] [Related]
16. Tumor-derived exosomes promote the in vitro osteotropism of melanoma cells by activating the SDF-1/cxcr4/CXCR7 axis.
Mannavola F; Tucci M; Felici C; Passarelli A; D'Oronzo S; Silvestris F
J Transl Med; 2019 Jul; 17(1):230. PubMed ID: 31324252
[TBL] [Abstract] [Full Text] [Related]
17. m
Yang S; Wei J; Cui YH; Park G; Shah P; Deng Y; Aplin AE; Lu Z; Hwang S; He C; He YY
Nat Commun; 2019 Jun; 10(1):2782. PubMed ID: 31239444
[TBL] [Abstract] [Full Text] [Related]
18. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
Caporali S; Amaro A; Levati L; Alvino E; Lacal PM; Mastroeni S; Ruffini F; Bonmassar L; Antonini Cappellini GC; Felli N; Carè A; Pfeffer U; D'Atri S
J Exp Clin Cancer Res; 2019 Jun; 38(1):272. PubMed ID: 31227006
[TBL] [Abstract] [Full Text] [Related]
19. Polyamine-stimulation of arsenic-transformed keratinocytes.
Alexander ET; Mariner K; Borodyanskaya Y; Minton A; Gilmour SK
Carcinogenesis; 2019 Aug; 40(8):1042-1051. PubMed ID: 31190067
[TBL] [Abstract] [Full Text] [Related]
20. [New molecular pathological strategies for malignant iris tumors].
Kakkassery V; Jünemann AM; Scheef BO; Grisanti S; Heindl LM
Ophthalmologe; 2019 Apr; 116(4):324-331. PubMed ID: 30623224
[TBL] [Abstract] [Full Text] [Related]
[Next]
